Updated Visitor Policy Regarding the Measles Outbreak. Read Policy

Decrease (-) Restore Default Increase (+)
CornerStone Vol. 24, No. 2 Fall 2014
Front page...

First-Rate Pulmonary Rehab Program Helps 9/11 First Responder Get His Life Back
NYU Winthrop Elects Two New Members to its Board of Directors
NYU Winthrop Opens Urgent Care Center
U.S. News & World Report Names NYU Winthrop Among the Best in the New York Metro Area
At NYU Winthrop, No Man is an Island
Spotlight on Community Gifts Campaign
Hospital Participates in Major International Trial
Generous Grant Supports Alzheimer's Research at NYU Winthrop
NYU Winthrop Opens New Center for Adult Congenital Heart Disease
New Treatment Improves the Lives of Patients With MR
Swimming with Purpose: Annual Event Raises Pivotal Support for Child Life Program
A Cause to Celebrate Raises More Than $147,000 for Child Life Program
A Celebration of Life: NYU Winthrop's 16th Annual Cancer Survivor's Day
Unique Partnership Supports Families Facing Perinatal Mood & Anxiety Disorders
29th Annual Golf Tournament Raises $649,000+ for NYU Winthrop Research and Academic Center
Eighth Annual Black & White Ball Raises Nearly $270,000 for NYU Winthrop's CCFK
Eight and Forty Makes Donation to Department of Pediatrics
Richard A. Newhouse, Jr., Receives Lifetime Achievement Award
Long Island Foundation's Generosity Changes Lives at NYU Winthrop's Hempstead Pediatric Clinic
Running for a Reason
National Awards Recognize Quality Breast Health Care
Once Again, NYU Winthrop Earns Designation as a NAEC Level 4 Epilepsy Center
New Patient Family Advisory Council
The STAR Program: Enhancing the Hospital Experience for Children With Special Needs
NYU Winthrop: A Pioneer in the Use of Technology to Enhance Patient Care and Safety
NYU Winthrop Debuts New Ambulances
Nurse Goes Above and Beyond the Call of Duty
NYU Winthrop Receives "Found Money"
Garden City Foundation Continues the Tradition of Making 'Miracles' for NYU Winthrop's CCFK
Twinkle Town Makes Colorful Donation to NYU Winthrop Kids
Milestone Golf Outing to Benefit the CCFK is a Record-Breaking Success
WiSH Clinic Opens
Surviving the Holidays
Hospital Celebrates Expansion With Dedication of New Specialty Center East
NYU Winthrop Unveils New "Welcome" Sign
NYU Winthrop Opens Manhattan's First and Only CyberKnife® Center

Hospital Participates in Major International Trial

Researchers at NYU Winthrop Hospital are participating in a major study funded by the National Institutes of Health (NIH) that could lead to an entirely new approach to preventing recurrent heart attacks in high risk patients. The main goal of the study, Cardiovascular Inflammation Reduction Trial (CIRT), is to discover whether reducing inflammation can lower one's risk of having a second heart attack, stroke, or dying from heart disease.

members of the winthrop research team Members of the NYU Winthrop Research Team who are participating in the NIH-funded CIRT Trial gather outside NYU Winthrop's new 95,000-square-foot Research and Academic Center, which is nearing completion and will house much of the Hospital's cutting-edge research initiatives.

CIRT is an international, multi-site trial supported by the National Heart, Lung and Blood Institute (NHLBI), a part of the NIH, that will investigate whether taking low-dose methotrexate, a widely used anti-inflammatory therapy for rheumatoid arthritis (RA), reduces cardiovascular events in individuals with type 2 diabetes or metabolic syndrome who have had a heart attack or multiple coronary blockages.

"NYU Winthrop was selected to participate in this trial because of the renowned ground-breaking research on autoimmune diseases such as RA and lupus already performed at the Hospital," said Alan M. Jacobson, MD, Chief Research Officer at NYU Winthrop. This research is conducted by Allison Reiss, MD, Head, Inflammation Section, NYU Winthrop Research Institute, and a team that includes Steven Carsons, MD, Chief of the Division of Rheumatology, Allergy and Immunology; Iryna Voloshyna, PhD, Research Associate; and Michael Littlefield, BA, Laboratory Technician. Dr. Reiss and the group identified in such patients the specific inflammatory components present in the circulatory systems that impair their cells' ability to metabolize cholesterol and, therefore, allow lipid accumulation in the artery, where it can lead to obstruction and heart attack. This research contributed to understanding the mechanisms through which several commonly used pain medications (COX inhibitors) elevate the risk for stroke and myocardial infarction.

"NYU Winthrop's contribution to the CIRT trial will be to examine how methotrexate affects cholesterol," said Dr. Reiss.

"Methotrexate does not just correct inflammation, but impacts how the cells handle cholesterol, which could in turn reduce one's risk of heart attack."

The CIRT research team consists of (pictured above, l.-r.) Dr. Jacobson; Dr. Voloshyna; Dr. Reiss; Wendy Drewes, BSN, RN, CCRC; Josh De Leon, MD, Director of the Cardiovascular Training Program, Director of Nuclear Cardiology and Director of Cardiovascular Research.

Dr. Reiss was sought out specifically by the head of the CIRT study, Paul Ridker, MD, who holds NYU Winthrop's research accomplishments in this area in high regard.

In research studies, inflammation (the body's complex response to injury in its attempts to control and heal injury) has been linked to atherothrombosis (the hardening and narrowing of the body's arteries), a primary cause of cardiovascular disease, which has led the investigators of this trial to ask whether or not reducing inflammation can educe cardiovascular events.

"This is the first systematic attempt to understand clinically the role of inflammation in the development of atherothrombosis," said Dr. De Leon. "It will give us new opportunities to treat patients, and potentially prevent recurrent cardiac events."

NYU Winthrop's research will take this a step further, since the Hospital has already laid the groundwork that shows the way in which methotrexate alters the metabolism of cholesterol in the cells that are in the walls of the arteries where atherothrombosis occurs. "We will be examining the blood and white blood cells of patients and looking for changes in cholesterol in response to methotrexate in the hopes that we can understand how it is beneficial, and perhaps predict in which patients it will do the most good," said Dr. Reiss.

NYU Winthrop is currently seeking participants for this study.

For more information on how to enroll in this trial, call 1-866-WINTHROP.